Phase II
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
Companies from across Europe, Asia and around the globe share pipeline and business updates.
Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”
Engage Therapeutics, Inc. announced that data from a phase 2a study of Staccato® alprazolam to suppress seizures in patients with epilepsy were published in the peer-review journal Epilepsia.
Cara Therapeutics, Inc. announced the initiation of a Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with atopic dermatitis.
SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites
Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction.
sterna biologicals GmbH & Co. KG (sterna) announced that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.
Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment
Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.
PRESS RELEASES